# Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.

Study · id `cardio:ct-nct04929600` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04929600](<https://clinicaltrials.gov/study/NCT04929600>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04929600

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04929600. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-28 (actual); primary completion 2023-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04929600, source copy `cardio:ctgov-nct04929600-2023-04-12`, retrieved 2026-10-26)
- Started: 2021-11-28 (actual) (ClinicalTrials.gov record NCT04929600, source copy `cardio:ctgov-nct04929600-2023-04-12`, retrieved 2026-10-26)
- Primary completion: 2023-06 (anticipated) (ClinicalTrials.gov record NCT04929600, source copy `cardio:ctgov-nct04929600-2023-04-12`, retrieved 2026-10-26)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT04929600, source copy `cardio:ctgov-nct04929600-2023-04-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04929600, source copy `cardio:ctgov-nct04929600-2023-04-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04929600-2023-04-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.
- Condition: Hypertension
- Condition: Left Ventricular Hypertrophy
- Intervention (Drug): sacubitril/valsartan
- Intervention (Drug): Amlodipine
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: 5bf03b1a5ab7b535d87bcbf8e462c076fc7a7455720ae74b8e91d07db2523dff
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
